Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.93
-0.36 (-0.15%)
AAPL  258.90
-0.14 (-0.06%)
AMD  206.19
+1.51 (0.74%)
BAC  56.12
-0.05 (-0.10%)
GOOG  330.45
+4.44 (1.36%)
META  651.61
+5.55 (0.86%)
MSFT  477.40
-0.71 (-0.15%)
NVDA  184.88
-0.16 (-0.08%)
ORCL  196.76
+7.61 (4.02%)
TSLA  444.73
+8.93 (2.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.